Asciminib in chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) patients now have improved life expectancy, yet many experience treatment failure with first- and second-generation tyrosine kinase inhibitors (TKIs).
• Treatment failure in CML is often caused by molecular resistance or severe toxicity, creating a need for novel therapeutic strategies.
• Asciminib represents a new class of targeted therapy for CML, offering a potential solution for patients with resistant or intolerant disease.

Approach:

• This review examines asciminib's role in CML treatment, focusing on its novel mechanism of action.
• Key aspects discussed include asciminib's pharmacokinetics, clinical efficacy, and safety profile.
• The review highlights asciminib's potential to overcome resistance mutations, including the challenging T315I mutation.

Key Points:

• Asciminib functions through allosteric inhibition, a distinct mechanism from traditional TKIs.
• This allosteric inhibition effectively bypasses common resistance pathways and reduces off-target toxicities.
• Asciminib demonstrates significant efficacy in preclinical and clinical studies for CML.

Conclusions:

• Asciminib is poised to significantly alter the CML therapeutic landscape.
• It offers a promising third-line treatment option for CML patients with resistant mutations or intolerance to other TKIs.
• The development of asciminib addresses a critical unmet need in managing advanced CML.